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The Bs vitamin antagonist 7-methyl-8dimethyl- 
amino-IOD-ribityl-isoalloxazine, roseoflavin (ROF) 
product of Streptomyces strain no. 768, discovered 
[ 1,2] has been shown to be a substrate of flavokinase 
(EC 2.7.1.26). The false nucleotide formed might be 
built into the apo-old yellow enzyme and thereby 
inhibit the oxidation of NADH and NADPH [3]. 
ROF in vitro (< 50 @g/ml) has no effect on the 
NADPH cytochrome c reductase, anlline hy~oxy~~ 
and ~~opy~e ~-demethylase activity of isolated 
liver microsomes (data not shown). We have found 
that in rats kept on normal diet (BZ vitamin cont. 
60 ppm), 4 mg/kg ROF (L&e 3 .OOO mg/kg in mice 
[I]) administered orally transiently prolongs the 
hexobarbital sleeping time (fig.1) showing that ROF’ 
in vivo is antagonist. The repeated administration of
ROF in similar doses increases the hexobarbital 
sleeping time both in non-induced and phenobarbital- 
induced animals. Now, we report the results of those 
experiments, where multiple doses of ROF were 
applied. 
2. Methods 
2.1. Animals 
Female Wistar (,Wi:RG)rats (loo-120 g) were kept 
on standard Lati food (containing 60 ppm vitamin B,) 
and water ad libitum. 
2.2. Drug a~~i~~st~ati~n 
Various amounts (l-4 mgfkg) of ROF suspended 
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Fig.1. Effect of a single oral dose of roseoflavin (ROF) on 
hexobarbital sleeping time. Vertical bars: SE of 6-9 deter- 
minations. Shaded area: control f SE. 
in water were administered by stomach tube at about 
8:00 a.m.; phenobarbital 60 mgjkg suspended in
water was given orally at about 9:00 a.m. Appropriate 
vehicle controls were included. Animals were treated 
daily for 3 days. The experiments were performed 
24 h after the last treatment, 
2.3. In vivo capacity of drug metabolism 
It was assessed by measuring the duration of 
sleeping time (from Ioss to retain righting reflex) after 
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an ix. injection of hexobarb~t~ (Evipan NatGum@) at 
a dose of 40 mgfkg. 
2.4, Assays on isolated microsomes 
The animals were sacrificed by decapitation and 
the livers were excised, chilled on ice and homogenized 
with a Teflon-glass homogenizer in 3 vol. 150 mM 
Xl, 50 mM Tris-HCl buffer (pH 7.4) at 0% The 
homogenate was centrifuged at 9OOOXg for 17 min. 
The supernatant was centrifuged at 105 OOOXg for 
60 min. The pellet was resuspended in 0.1 M Tris-HCl 
buffer (pH 7.5) 
Aniline hydroxylase activity was assayed in a 
medium containing 2mgfml microsomal protein 
suspended in 0.1 M Tris-HCl buffer (pH 7.5); S mM 
MgCl, ; 1 .O mM NADPH and 4 mM aniline, Incubation 
was carried out at 37°C for 15 min. 
The paminophenol formed was measured as in [41. 
N-demethylase activity was performed in a reaction 
mixture containing 1.5 mgfml microsomal protein 
suspended in 0.1 M Tris-HCl buffer fpH 7.5); 5 mM 
MgCl;? ; 1 .O mM NADPH and 8 mM am~opyr~e for 
10 min at 37% The fo~~dehyde formed was 
determined by the method in [S] . Cytochrome P-450 
was measured by the method in [6] a NADPH-cyto- 
chrome c (P450) reductase (EC 1.6.2.3) activity was 
assayed as in [7]. 
3. Results 
In preliminary experiments we have found that 
ROF (G 50 &g/ml) in vitro has no effect on the liver 
microsomal dru~metabo~z~g enzymes, however, 
in vivo this new Ba vitamin antagonist in low doses 
influences the microsomal drug-metabolizing enzyme 
activity of rats kept on normal diet. A single 4 mg/kg 
ROF dose per os transiently prolongs the hexobarbital 
sleeping time. The most probable xplanation for this 
phenomenon isthat a false coenzyme is produced in 
the organism. 
Repeated ROF adm~istration prolongs hexo- Repeated adm~istrat~on f ROF both in non- 
barbital sleeping time both in non-induced and pheno- induced and phenobarbit~-educed groups increases 
barbital-educed rats (table 1). This result indicates the sleeping time 24 h after the last treatment >
that the B2 antagonist RUF slows down biotransfor- 
mation of hexobarbital. 
Repeated ROF treatment did not influence the 
cytochrome P450 concentration i  liver microsomes. 
Phenobarbital nd ROF administered simultaneously 
increased the &GO concentration to a higher level 
than phenobarbital one (fg.2). ROF treatment 
decreased the activity of NADPHcytochrome c(&GO) 
reductase, In the livers of animals ~ult~eou~y 
treated with pbenob~bit~ and ROF the NADPH- 
cytochrome c (P-450) reductase activity was inhibited 
depending on the RUF doses. The diminution of 
reductase activity on the RUF treatment was identical 
in control and phenobarbital-treated groups (figd). 
The aminopyrine demethylase and aniline hydroxylase 
activity of isolated microsomes was not significantly 
decreased under the effect of ROF treatment #g&,5). 
4. Discussion 
Table 1 
Effect of roseoflavin (ROF) on hexobarbital sleeping time in control and 
phenobarbital-induced rats 
Hexobarbital sleeping time (min + SE) 
0 mg ROE/kg 1 .O mg ROF/kg 2 .O mg ROF/kg 4.0 mg ROF/kg 
Control 2.5.7 f 2.21 (39) ND.a N.D.a 34.0 +_ 2.14 (32)b 
Induced 5.9 I 0.32 (39)c 11.5 * 1.18 (15)’ 13.2 2: 1.52 (iQc 10.6 i 0.90 (32)c 
a not determined 
bP< O.05 
’ P < 0.01 compared to induced and ROF non-treated group 
no. animals are in parenthesis 
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Fig.Z.CytochromeP450 concentration in the liver of control 
and pretreated rats (mean f SD, ~8): ROF, roseoflavin; 
PhB, phenobarbital. *p < 0.01, **p < 0.05. 
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Fig.3. NADPH-cytochrome (P450) activities in the liver of 
control and pretreated rats. (mean f SD, n=8): §p < 0.01, 
control; *p < 0.01, PhB-treated group. 
Fig.4.Ndemethylase activity in the liver microsomes of 
control and pretreated rats (mean f SD, n=8). 
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Fig.5. Aniline hydroxylase activity in the liver microsomes of 
control and pretreated rats (mean c SD, n=8). 
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~dicating the slower biotr~sfo~ation of hexo- 
barbital in vivo . The aniline hydroxylase and amino- 
pyrine Ndemethylase activities were not changed 
significantly in rats pretreated with ROF or ROF 
plus phenobarbital. Thus, in these experimental con- 
ditions th.e in vitro parameters of metabolism are 
inconsistent with the in vivo results. The NADPII- 
cytochrome c (P-450) reductase activity decreases in
a dose-dependent fashion after repeated ROF admini- 
stration. In the ROF-treated animals the liver cyto- 
chrome P450 content was unchanged. If ROF is 
given together with phenobarbit~, the elevation of 
cytochrome f450 content is higher than in the 
phenobarbital-induced group. This result was 
unexpected since the applied phenobarbital dose 
alone causes maximal induction. 
Our results indicate some probems concerning 
the microsomal drug metabolism. First, the in vivo 
and in vitro tests for drug metabolism do not parallel 
each other. Moreover, the in vitro assays themselves 
are contradictor . The aniline hydroxylase and 
~demethylase activities did not change si~~ic~~y 
after repeated treatments with ROF, and at the same 
time N~P~~ytochrome c (P450) reductase activity 
and the cytochrome P450 content - thought o be 
ratedimiting [S-l 1 ] - changed considerably in the 
opposite direction. 
Thus, this Bz vitamin antagonist eems to be a 
useful tool for the comparative study of the mecha- 
nism of microsomal drug enzyme induction in vivo 
and in vitro. 
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